Back HIV/AIDS HIV/AIDS Topics HIV Treatment EACS 2013: HIV Rebound Linked to Higher Baseline Level, Slower Suppression, Low-level Viremia

EACS 2013: HIV Rebound Linked to Higher Baseline Level, Slower Suppression, Low-level Viremia

alt

Higher baseline viral load, longer time to viral suppression, and low-level viremia below the level of detection of standard tests raise the risk of viral rebound among people with HIV on antiretroviral therapy (ART), according to a pair of studies presented at the 14thEuropean AIDS Conference this month in Brussels.

Only about 20%-25% of people with HIV in the U.S., Europe, and sub-Saharan African are on ART with full viral suppression, while the remainder fall out at various stages of the "treatment cascade." Lack of access and poor adherence are known problem areas, but reasons for loss of virological control among people who achieve viral suppression are not fully understood.

Laura Waters from Mortimer Market Centre in London reported findings from a study of the effects of baseline viral load and time to viral suppression on risk of viral rebound among participants receiving first-line combination ART in the UK Collaborative HIV Cohort. UK CHIC regularly collects data from HIV positive adults attending 13 centers for HIV care, including demographic information, ART treatment history, clinical events, and lab test results.

Several clinical trials have shown lower rates of viral suppression amongst people with high baseline viral load, but the impact of high pre-treatment viral load on longer-term virological outcomes in patients who achieve viral suppression is unknown, the researchers noted as background.

Eligible participants were selected from amongst 14,477 treatment-naive UK CHIC patients who started treatment with combination ART including a protease inhibitor or non-nucleoside reverse transcriptase inhibitor (NNRTI) after the year 2000. People who started ART within 3 months of HIV diagnosis, experienced AIDS events within 3 months after starting ART, or lacked follow-up date were excluded, leaving 8184 individuals.

Out of this group, 7475 people (91%) achieved viral suppression on their initial ART regimen and were included in the main analysis. Rates of suppression were 92% for people with viral load <10,000 or 10,000-100,000 copies/mL at baseline, 91% for those with 100,000-500,000 copies/mL, and 87% for those with >500,000 copies/mL.

Participants in the main analysis were mostly men (80%), two-thirds were white, one-quarter were black, and the median age was 38 years; 65% were men who have sex with men and 29% were heterosexual. The median baseline CD4 T-cell count was 245 cells/mm3. All started 3-drug combination ART with 76% starting on a NNRTI-based regimen and 24% starting on a protease inhibitor. Looking at baseline viral load, 23% had <10,000 copies/mL, 42% had 10,000-100,000 copies/mL, 30% had 100,000-500,000 copies/mL, and only 5% had >500,000 copies/mL.

Results

  • Most participants achieved viral suppression to <50 copies/mL either within 3 months (42%) or 3-6 months (40%) after starting first-line ART; however, 15% did so between 6 and 12 months after starting therapy, and 5% took longer than a year to reach undetectable viral load.
  • A total of 1289 participants (17%) experienced viral rebound -- defined as 2 consecutive measures >50 copies/mL -- during a median follow-up period of 3.5 years.
  • Adjusting for other factors, the probability of viral rebound was significantly higher for people who started treatment with 100,000-500,000 copies/mL (hazard ratio [HR] 1.34, or 34% higher than those with 10,000-100,000 copies/mL) and highest for those with >500,000 copies/mL (HR 1.67).
  • Viral rebound rates also rose significantly for people who took 6-12 months to achieve suppression (HR 1.47 compared to those who took 3-6 months), and even more so for those who took longer than a year (HR 2.49, or nearly 2.5-fold higher risk).
  • Patterns for both baseline viral load and time to viral suppression were similar when looking separately at people who started NNRTIs and those who started protease inhibitors.
  • Again, people with the 2 highest baseline viral load levels and those who took either 6-12 months or more than a year to achieve viral suppression were at significantly greater risk for viral rebound.
  • The overall median CD4 cell rise between baseline and time of viral suppression was 115 cells/mm3, but gains rose with baseline viral load: 69 cells/mm3 for those with <10,000 copies/mL, 110 cells/mm3 for those with 10,000-100,000 copies/mL, 153 cells/mm3 for those with 100,000-500,000 copies/mL, and 187 cells/mm3 for those with >500,000 copies/mL.
  • CD4 cell gains were likewise larger for those who took longer to achieve viral suppression: 75 cells/mm3 for those who took less than 3 months, 135 cells/mm3 for those taking 3-6 months, 180 cells/mm3 for those taking 6-12 months, and 190 cells/mm3 for those taking more than a year.

"Baseline viral load correlated significantly with achievement of viral suppression on initial combination ART," the researchers concluded. "Amongst individuals who have achieved viral suppression on first-line combination ART, higher baseline viral load and slower time to suppression were also associated with a higher chance of subsequent virological rebound."

Although this study was limited by lack of adherence data, Waters noted that all participants included in the main analysis managed at least good enough adherence to achieve undetectable viral load.

"[T]his study adds to the trial data that suggests we may need to investigate new strategies, with modern drugs, for individuals with high pre-treatment viral load," the investigators added. "We recommend that patients with high baseline viral load should continue to be monitored closely, even after virological suppression, as they remain at higher risk of rebound."

Anecdotally, Waters said, her group has been trying Atripla (efavirenz/tenofovir/emtricitabine) plus raltegravir (Isentress) for people starting treatment with very high viral load.

Low-level Viremia

In a related study, Andrea Calcagno from the University of Torino in Italy and colleagues evaluated whether residual low-level virus while on ART and other clinical factors raise the risk of viral rebound over 2 years among people who have achieved "undetectable" viral load according to standard tests.

Low-level viremia can persist for years among patients on suppressive ART and may be associated with immune activation, the researchers noted as background. Treatment intensification by adding more drugs does not eliminate low-level viremia, but some data indicate levels may be lower in people using NNRTIs, especially nevirapine (Viramune).

This retrospective analysis included 1065 people with HIV on combination ART who had at least 2 consecutive HIV RNA measurements <50 copies/mL between the first half of 2010 and the second half of 2012. Most (72%) were men, the mean age was 47 years, and nearly 30% were coinfected with hepatitis C.

Participants had been HIV positive for 13 years on average and had undetectable viral load for 3 years. The mean current CD4 count was 587 cells/mm3, with a mean nadir (lowest-ever level) of 220 cells/mm3. Equal proportions were taking protease inhibitors and NNRTIs (about 41% for each) while 4% were taking raltegravir; 76% also used tenofovir (Viread, also in Truvada and single-tablet regimens).

The researchers measured viral load using a sensitive assay (CAP/CTM Roche TaqMan v. 2.0) that gave results of "target not detected" (TND), <20 copies/mL, or 20-50 copies/mL. Viral rebound was again defined as 2 consecutive viral loads >50 copies/mL.

Results

  • At baseline, 78%, 77%, and 70% of people taking raltegravir, NNRTIs, and protease inhibitors, respectively, had a measurement showing "target not detected," with the difference reaching statistical significance.
  • 10%, 19%, and 20%, respectively, had <20 copies/mL, while 12%, 10%, and 10% had 20-50 copies/mL.
  • In an adjusted multivariate analysis, the only 3 factors that independently predicted absence of low-level viremia ("target not detected") were female sex (adjusted odds ratio [OR] 1.69), CD4 nadir above 200 cells/mm3 (adjusted OR 1.32), and use of either raltegravir or NNRTIs (adjusted OR 1.24 compared to protease inhibitors).
  • Overall, 8% of participants experienced viral rebound at 2 years, a proportion that remained the same when looking at the 867 people who did not change their ART regimen.
  • Rebound occurred in 7% of people without low-level viremia, 11% with <20 copies/mL, and 16% with 20-50 copies/mL.
  • The duration of viral suppression was about 30 months for people who experienced rebound compared to 50 months for sustained responders.
  • Independent predictors of viral rebound were female sex (adjusted OR 1.79), hepatitis C coinfection (adjusted OR 1.68), viral suppression <50 copies/mL for less than 2 years (adjusted OR 2.11), low-level viremia (<20 or 20-50 copies/mL) at baseline (adjusted OR 1.75), and using protease inhibitors (adjusted OR 2.48, or nearly 2.5-fold higher risk).

A risk score comprised of these variables -- low risk if 0-2 factors or high risk if >2 factors -- accurately predicted viral rebound, which occurred in 5% of those with a low risk score compared to 19% of those with a high risk score.

In thisstudy, low-level viremia predicted virological rebound at 2 years of follow-up, the researchers concluded.

 

However, they noted, the use of a lower cut-off for defining complete viral suppression is called into question by the few available interventions in case of low-level viremia, possibly including adherence counselling or switching to a NNRTI-based regimen.

10/30/13

References

S Jose, LJ Waters, S Edwards, et al. The impact of baseline viral load (VL) and time to viral suppression on treatment responses to first-line combination antiretroviral therapy (cART). 14th European AIDS Conference (EACS 2013). Brussels. October 16-19, 2013. Abstract PS7/3.

A Calcagno, V Ghisetti, S Lo Re, et al. Level of HIV Viremia below 50 copies/ml predicts virologic rebound in HAART-treated patients. 14th European AIDS Conference (EACS 2013). Brussels. October 16-19, 2013. Abstract PS7/4.